KalVista Pharmaceuticals, Inc.KALVEarnings & Financial Report
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel oral serine protease inhibitor therapies. Its core pipeline addresses unmet medical needs for rare and inflammatory diseases including hereditary angioedema and diabetic macular edema, with primary target markets in North America and Europe.
KALV Q2 FY2026 Key Financial Metrics
Revenue
$13.7M
Gross Profit
$12.5M
Operating Profit
$-46.0M
Net Profit
$-49.5M
Gross Margin
91.0%
Operating Margin
-336.3%
Net Margin
-361.4%
YoY Growth
N/A
EPS
$-0.92
KalVista Pharmaceuticals, Inc. Q2 FY2026 Financial Summary
KalVista Pharmaceuticals, Inc. reported revenue of $13.7M for Q2 FY2026, with a net profit of $-49.5M (down 17.1% YoY) (-361.4% margin). Cost of goods sold was $1.2M, operating expenses totaled $58.5M.
Key Financial Metrics
| Total Revenue | $13.7M |
|---|---|
| Net Profit | $-49.5M |
| Gross Margin | 91.0% |
| Operating Margin | -336.3% |
| Report Period | Q2 FY2026 |
KalVista Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
KalVista Pharmaceuticals, Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $13.7M | — | $-49.5M | -361.4% |
| Q1 FY2025 | $0 | — | $-40.4M | N/A |
Income Statement
| Q1 2025 | Q2 2026 | |
|---|---|---|
| Revenue | $0 | $13.7M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2026 | |
|---|---|---|
| Assets | $200.2M | $339.9M |
| Liabilities | $27.4M | $322.9M |
| Equity | $172.8M | $17.0M |
Cash Flow
| Q1 2025 | |
|---|---|
| Operating CF | $-40.2M |